Artelo Biosciences, Inc. Warrant
ARTLW
ARTLW was delisted on the 17th of June, 2024.
5 hedge funds and large institutions have $748 invested in Artelo Biosciences, Inc. Warrant in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
67% more funds holding
Funds holding: 3 → 5 (+2)
55% less capital invested
Capital invested by funds: $1.66K → $748 (-$910)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$100 |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$6 |
Top Sellers
ARTLW Hedge Fund Activity: Q1 2024 in Review
5 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences, Inc. Warrant (ARTLW) for Q1 2024, worth a combined $748 — down 55% from $1.66K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ARTLW positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $100.
- 5 institutional investors held Artelo Biosciences, Inc. Warrant (ARTLW) as of Q1 2024, up from 3 in Q4 2023.
- Funds reported $748 of Artelo Biosciences, Inc. Warrant stock for Q1 2024, down 55% quarter-over-quarter.
- 2 funds opened new Artelo Biosciences, Inc. Warrant positions in Q1 2024 and 0 closed out, a net change of +2 holders.
- The largest Artelo Biosciences, Inc. Warrant buyer in Q1 2024 was UBS Group, an estimated $100 added.
Based on aggregated 13F filings for Q1 2024.